CD38 and acute lymphoblastic leukemia: Given the advanced status of anti-CD38 antibodies in the clinics, two different clinical trials are now testing the efficacy of Daratumumab (NCT03384654) and Isatuximab (NCT03860844) for r/r B- or T-ALL (Table 1).